1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2014

Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2014" provides data on the Multiple Myeloma (Kahler’s Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Myeloma (Kahler’s Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Myeloma (Kahler’s Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Multiple Myeloma (Kahler's Disease) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Myeloma (Kahler's Disease) 25
Subjects Recruited Over a Period of Time 42
Clinical Trials by Sponsor Type 43
Prominent Sponsors 44
Top Companies Participating in Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials 45
Prominent Drugs 47
Latest Clinical Trials News on Multiple Myeloma (Kahler's Disease) 48
Oct 01, 2014: Innate Pharma Announces Initiation of a Phase I clinical trial of Lirilumab in combination with elotuzumab 48
Sep 25, 2014: Novel Compound Prevents Metastasis of Multiple Myeloma in Mouse Studies 48
Sep 04, 2014: Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple Myeloma 49
Aug 25, 2014: Patrys Releases Details of PAT-SM6 and Carfilzomib Clinical Trial 50
Aug 11, 2014: Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma 50
Clinical Trial Profiles 52
Clinical Trial Overview of Top Companies 52
Celgene Corporation 52
Clinical Trial Overview of Celgene Corporation 52
Takeda Pharmaceutical Company Limited 64
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 64
Amgen Inc. 71
Clinical Trial Overview of Amgen Inc. 71
Novartis AG 77
Clinical Trial Overview of Novartis AG 77
Johnson and Johnson 83
Clinical Trial Overview of Johnson and Johnson 83
Sanofi 88
Clinical Trial Overview of Sanofi 88
F. Hoffmann-La Roche Ltd. 91
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 91
Bristol-Myers Squibb Company 94
Clinical Trial Overview of Bristol-Myers Squibb Company 94
Merck and Co., Inc. 96
Clinical Trial Overview of Merck and Co., Inc. 96
Pfizer Inc. 98
Clinical Trial Overview of Pfizer Inc. 98
Clinical Trial Overview of Top Institutes / Government 100
National Cancer Institute 100
Clinical Trial Overview of National Cancer Institute 100
Fred Hutchinson Cancer Research Center 107
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 107
University of Texas M. D. Anderson Cancer Center 112
Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center 112
University of Arkansas 115
Clinical Trial Overview of University of Arkansas 115
Mayo Clinic 118
Clinical Trial Overview of Mayo Clinic 118
Memorial Sloan Kettering Cancer Center 121
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 121
Sidney Kimmel Comprehensive Cancer Center 124
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 124
Washington University School of Medicine 126
Clinical Trial Overview of Washington University School of Medicine 126
Barbara Ann Karmanos Cancer Institute 128
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 128
Five Key Clinical Profiles 130
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Source 182

List of Tables

Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Multiple Myeloma (Kahler's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Myeloma (Kahler's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Multiple Myeloma (Kahler's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Myeloma (Kahler's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Terminated Clinical Trials, 2014* 30
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 42
Multiple Myeloma (Kahler's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 43
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 44
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 46
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 47
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 52
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 64
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 71
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 77
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 83
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 88
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 91
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 94
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 96
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 98
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 100
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 107
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2014* 112
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014* 115
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 118
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 121
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 124
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 126
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 128

List of Figures
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Multiple Myeloma (Kahler's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Myeloma (Kahler's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Myeloma (Kahler's Disease) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Multiple Myeloma (Kahler's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Myeloma (Kahler's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Myeloma (Kahler's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 42
Multiple Myeloma (Kahler's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 43
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 44
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 45
Multiple Myeloma (Kahler's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 47
GlobalData Methodology 181

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.